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Abstract
Background: Trichosporon species are ubiquitously spread and known to be part of the normal human flora of the
skin and gastrointestinal tract. Trichosporon spp. normally cause superficial infections. However, in the past decade
Trichosporon spp. are emerging as opportunistic agents of invasive fungal infections, particularly in severely
immunocompromised patients. Clinical isolates are usually sensitive to triazoles, but strains resistant to multiple
triazoles have been reported.
Case presentation: We report a high-level pan-azole resistant Trichosporon dermatis isolate causing an
invasive cholangitis in a patient after liver re-transplantation. This infection occurred despite of fluconazole
and low dose amphotericin B prophylaxis, and treatment with combined liposomal amphotericin B and
voriconazole failed.
Conclusion: This case and recent reports in literature show that not only bacteria are evolving towards
pan-resistance, but also pathogenic yeasts. Prudent use of antifungals is important to withstand emerging
antifungal resistance.
Keywords: Trichosporon dermatis, Disseminated trichosporonosis, Invasive fungal disease, Antifungal
stewardship, Liver transplant
Background
The genus Trichosporon with its yeast-like anamorphic
cells belongs to the phylum of the Basidiomycota [1].
Trichosporon spp. are present ubiquitously and are
known to be part of the normal human flora of the skin
and gastrointestinal tract. In otherwise healthy individ-
uals Trichosporon spp. may cause infections like white
piedra or skin infections. However, in the past decade,
Trichosporon spp. are emerging as opportunistic agents
of invasive fungal infections, particularly in severely im-
munocompromised patients such as hematological pa-
tients and solid organ transplant recipients [2–4]. These
patients commonly receive antifungal prophylaxis to
prevent invasive fungal infections. Prolonged or
recurrent usage of antifungal agents may select for in-
trinsically resistant fungi, or cause acquisition of resist-
ance in wild-type susceptible fungal species.
Here we present the first case of treatment failure of
cholangitis caused by a pan-azole resistant Trichosporon
dermatis, and we review the literature for voriconazole
resistance in Trichosporon spp.
Case presentation
A 48-year-old male patient was admitted to our hospital
with spontaneous bacterial peritonitis (SBP) and hepatic
encephalopathy. He had received a liver transplant
20 years ago for cryptogenic liver cirrhosis. Recently, he
had suffered from progressive chronic transplant failure
for which he had been repeatedly admitted due to
decompensated liver cirrhosis. Other relevant diseases of
the patient’s medical history are colitis ulcerosa and
diabetes mellitus type II.
The patient was treated with ceftriaxone (2000 mg q.d.
IV) for SBP caused by E. coli. After two weeks, the
patient became febrile again due to recurrent SBP, for
which he empirically received meropenem (1000 mg
b.i.d. IV), later switched to piperacillin/tazobactam
(4000/500 mg t.i.d. IV). These therapies lead to a clinical
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and biochemical improvement. He became well enough
to be listed for liver re-transplantation, which was
performed 2 weeks later from a heart beating donor.
The preoperative modal for end-stage liver disease
(MELD) score was 40 and the portal vein was throm-
bosed. The transplant procedure was characterized by a
very difficult hepatectomy due to massive adhesions,
portal hypertension and thickened peritoneum. An
attempt to perform thrombectomy of the portal vein
was unsuccessful and the donor portal vein had to be
anastomosed with a large dilated side branch of the
superior mesenteric vein using a iliac vein interposition
graft. Because of massive ongoing blood loss the
abdomen had to be packed with gauzes. The immediate
postoperative course was complicated by primary non-
function of the liver graft and portal vein thrombosis,
requiring a re-re-transplant two days later. After this re-
re-transplant the abdominal wall could not be closed
due to massive distension of the viscera. The abdomen
was temporarily closed with a silastic mesh. The patient
was treated with prophylactic low dose amphotericin B
(0.3 mg/kg q.d. IV), fluconazole (100 mg q.d. IV) and
piperacillin/tazobactam (4000/500 mg t.i.d. IV) as part
of the post-transplantation protocol and selective decon-
tamination of the digestive tract (SDD) regime on the
intensive care unit (ICU) consisting of 2 % polymyxin B,
2 % tobramycin and 2 % amphotericin B in a suspension
(0.5 gram q.d.s.) and oral paste in the mouth. On day
seven after the second transplantation the patient clinic-
ally deteriorated due to an abdominal compartment
syndrome. Cultures taken from the abdominal drains
5 days later yielded Trichosoporon species. Additional
samplings from the 4 abdominal drains in situ were also
positive for Trichosporon. Species determination by Matrix
Assisted Laser Desorption Ionization-Time of Flight
mass spectrometry (MALDI-TOF MS, Bruker) showed
T. mucoides with a score of 2.17. Molecular sequencing
of the internal transcriber spacer (ITS) and cytochrome B
gene (cytB) by CBS-KNAW Fungal Biodiversity Center,
Utrecht, The Netherlands (Fig. 1), conclusively identified
the isolate as T. dermatis (deposited in Genbank under
accession numbers KT597976 and KT597975, respectively
and Treebase under submission number S18915). The
isolate has been deposited in the CBS-KNAW Fungal
Biodiversity Center under catalog number CBS14086.
Table 1 shows the MICs for all antifungal agents
tested. Amphotericin B prophylaxis was switched to
liposomal amphotericin B (5 mg/kg q.d. IV) and flucona-
zole was switched to voriconazole (200 mg b.i.d. IV).
Tapering of immunosuppressive therapy (hydrocortisone
4 mg/h continuous IV) was not deemed feasible. The
remaining anti-rejection therapy consisted of basiliximab
20 mg on day 0 and day 4 after transplantation.
Three days later the abdomen was re-explored and the
silastic mesh was removed. Cultures from fibrin clots
and fluid collections behind the vena cava, suprahepatic
material, gallbladder fluid and pleural fluid all yielded
pure cultures of T. dermatis, which lead to the diagnosis
invasive fungal cholangitis. After 1 week of treatment,
T. dermatis was still cultured from drain fluid. The
patient died on the 29th day after the last liver trans-
plantation due to multi-organ failure with persistent
trichosporonosis.
Conclusion
Our T. dermatis isolate was highly resistant to all triazoles,
echinocandins, and 5-flucytosine. The patient had been
treated with several courses of broad-spectrum antibiotics
and antifungal agents for abdominal infections in recent
history, and received antifungal prophylaxis with low dose
fluconazole and low dose amphotericin B when the
infection occurred. He also received SDD. The anti-
microbial pressure with broad-spectrum antibacterial
drugs (reduced competition) and relatively low dose
Fig. 1 Rooted phylogenetic tree of the Trichosporon isolate based on confidently aligned ITS and cytB sequences, obtained by maximum
parsimony cluster analysis and 1000 bootstrap simulations
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antifungals has most likely contributed to the selection of
this highly resistant isolate.
Wild-type Trichosporon spp. are susceptible to triazoles,
that target the lanosterol 14 alpha-demethylase of the
ergosterol pathway. From 2003, fluconazole resistance has
increasingly been reported [5–7]. Voriconazole is the most
effective antifungal agent against Trichosporon spp. and is
recommended as treatment for trichosporonosis [8]. How-
ever, from 2010 onward the first sporadic cases of Trichos-
poron spp. resistant to voriconazole were reported [9,10],
and a recent study from Greece reported that 38 % of
Trichosporon isolates had a MIC ≥ 2 mg/L for voricona-
zole [11]. Most of these strains were susceptible to at least
one other triazole, and treatment failures were not
described in this study. An overview of susceptibilities of
T. dermatis described in literature is presented in Table 1.
This shows that T. dermatis are generally susceptible to
voriconazole and itraconazole, and underlines the excep-
tional level of resistance of our isolate.
Invasive trichosporonosis is a life-threatening condi-
tion and optimization of antifungal therapy in an early
stage of infection is essential. A provisional susceptibility
pattern based on Etests® indicated resistance to flucona-
zole, with a low MIC for voriconazole (0.094 mg/l).
Based on this, we started treatment with both voricona-
zole and liposomal amphotericin B. The effectiveness of
amphotericin B is very low, probably due to its poor
killing activity against Trichosporon spp. [5,12]. Nonethe-
less, it is the only treatment option left in case of high-
level resistance to triazoles, since Trichosporon spp. are
intrinsically resistant to echinocandins and flucytosine [8].
Voriconazole resistance was later confirmed by micro-
broth dilution method by the national reference center
(Radboud University Medical Center, Nijmegen, the
Netherlands). The combination of long standing im-
mune suppression, a difficult re-transplant complicated
by primary non-function of the graft and infection with
a multi-resistant isolate resulted in failure of treatment.
Prudent use of antifungals is important to withstand
emerging antifungal resistance. Effectiveness of flu-
conazole or low dose amphotericin B as antifungal
prophylaxis in high-risk liver transplant patients in
prevention of invasive candidiasis is evidence-based,
and recommended by Infectious Diseases Society of
America (IDSA) guidelines [13]. Prophylaxis prevents
morbidity and mortality caused by Candida albicans
[14,15]. From an antifungal stewardship point of view,
fluconazole is preferred for its narrow spectrum, and
amphotericin B could be reserved for those patients
colonized with fluconazole resistant yeasts. Antifungal
prophylaxis for at least 7-14 days postoperative in
high-risk patients, and during ICU stay, is recom-
mended [13].
Correct species identification is important for epide-
miologic reasons, species-specific virulence and resist-
ance characteristics. For T. dermatis bi- or multi-locus
sequence analysis with e.g. ITS and cytB allows unambigu-
ous identification. Misidentification of T. dermatis as T.
mucoides occurs, but is most likely when only biochemical
tests are performed [7]. Next to T. asahii (74 %), T.
dermatis is the second most reported species (12 %) caus-
ing invasive infections, but T. mucoides is rarely involved
in invasive infections [3].
We conclude that our study shows that not only
bacteria are evolving towards pan-resistance, but also
pathogenic yeast species belonging to Trichosporon. Anti-
fungal resistance is a serious threat for health care of
immunocompromised patients.
Consent
Written informed consent was obtained from the
patients’ next of kin (wife), due to the fact that the
patient himself was not able to sign himself, for
publication of this Case Report and any accompany-
ing images. The consent was obtained five days before
his death.
Table 1 MICs of various antifungal agents against 11 clinical Trichosporon dermatis isolates
T. dermatis
strains tested
MIC (mg/liter) Method Reference
Amphotericin
Ba
Flucytosine Fluconazole Itraconazole Voriconazole Posaconazole Caspofungin
GM Range GM Range GM Range GM Range GM Range GM Range GM Range











ND ND Eucast Rodriguez-Tudela
et al 2005 [7]
1 0.5 8 0.06 0.06 ND 16 CLSI Chagas-Neto
et al 2009 [2]
1 0.13 ND 2 0.06 0.06 0.015 ND Eucast Taverna et al. 2014 [16]
GM geometrical mean, MIC minimal inhibitory concentration, ND not done
aEffectiveness of amphotericin B is limited in Trichosporon infections [12]
bSusceptibility was tested using a commercial microdilution test (Yeast Sensititre OneTM) by the national reference center (Radboud University Medical Center,
Nijmegen, The Netherlands)
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under accession URL: http://purl.org/phylo/treebase/
phylows/study/TB2:S18915 and submission number
18915 for Treebase.
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